IPO - Profile


We are a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. Our vision is to elevate precision medicine to the forefront of every cancer treatment journey, as we believe that each patient living with cancer deserves the opportunity to benefit from a genomically-driven treatment decision. We utilize our deep expertise in developing drugs for rare, genomically-defined patient populations and strategic collaborations with our diagnostic collaborators to work towards a future where each tumor’s unique genomic test result can be More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$16.00 6,250,000 Positive High 35.66%

Offering Team

  • Legal counsel
  • Fenwick & West LLP
  • Auditors
  • CohnReznick LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 24 Jun, 2021

Offer 25 Jun, 2021

Look Ahead

Lock Up Expiry Dec 25, 2021

IPO Terms

Offer Price $16.00
Offer Size 6M

Market Sentiments

Stock Price